Philadelphia Business Journal -- GlaxoSmithKline has settled 5,500 cases related to its diabetes drug Avandia for $250 million, or an average of $46,000 each, the Philadelphia Inquirer reports in a Bloomberg story.
LONDON ( Reuters ) - GlaxoSmithKline Plc has agreed in principle to settle several long-standing disputes with the U.S. government over the way it marketed and developed drugs, at a cost of $3...
Read Full Story »